Clomicalm

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

clomipramine hydrochloride

Available from:

Virbac S.A.

ATC code:

QN06AA04

INN (International Name):

Clomipramine

Therapeutic group:

Кучета

Therapeutic area:

Psychoanaleptics

Therapeutic indications:

As an aid in the treatment of separation related disorders in dogs manifested by destruction and inappropriate elimination (defecation and urination) and only in combination with behavioural modification techniques.

Product summary:

Revision: 18

Authorization status:

упълномощен

Authorization date:

1998-04-01

Patient Information leaflet

                                15
B. ЛИСТОВКА
16
ЛИСТОВКА:
КЛОМИКАЛМ 5 MG ТАБЛЕТКИ ЗА КУЧЕТА
КЛОМИКАЛМ 20 MG ТАБЛЕТКИ ЗА КУЧЕТА
КЛОМИКАЛМ 80 MG ТАБЛЕТКИ ЗА КУЧЕТА
1.
ИМЕ И ПОСТОЯНEН АДРЕС НА ПРИТЕЖАТЕЛЯ
НА ЛИЦЕНЗА ЗА УПОТРЕБА
И НА ПРОИЗВОДИТЕЛЯ, АКО ТЕ СА РАЗЛИЧНИ
Притежател на лиценза за употреба и
производител, отговорен за
освобождаване на партидата:
VIRBAC
1ère Avenue – 2065 m – L.I.D.
06516 Carros
France
2.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Кломикалм 5 mg таблеткиза кучета
Кломикалм 20 mg таблетки за кучета
Кломикалм 80 mg таблетки за кучета
Кломипрамин хидрохлорид
3.
СЪДЪРЖАНИЕ НА АКТИВНАТАСУБСТАНЦИЯ И
ЕКСЦИПИЕНТ ИТЕ
5 mg clomipramine hydrochloride (еквивалентен на 4,5 mg
clomipramine)
20 mg clomipramine hydrochloride (еквивалентен на 17,9
mg clomipramine)
80 mg clomipramine hydrochloride (еквивалентен на 71,7
mg clomipramine)
5 mg таблетка: кафяво-сива,
овално-продълговата, делима. Черти от
двете страни.
20 mg таблетка: кафяво-сива,
овално-продълговата, делима. С
маркировка ‘C/G’ от едната
страна, ‘G/N’ от другата и черти от
двете страни.
80 mg таблетка: кафяво-сива,
овално-продълговата, делима. С
маркировка ‘I/I’ от едната
страна, без маркировка от другата и
черти от двете страни.
4.
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Като
помощно
средство
при
лече
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Кломикалм 5 mg таблетки за кучета
Кломикалм 20 mg таблетки за кучета
Кломикалм 80 mg таблетки за кучета
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Всяка таблетка Кломикалм съдържа:
АКТИВНА СУБСТАНЦИЯ:
Clomipramine hydrochloride
5 mg (еквивалентен на 4,5 mg clomipramine)
Clomipramine hydrochloride
20 mg (еквивалентен на 17,9 mg clomipramine)
Clomipramine hydrochloride
80 mg (еквивалентен на 71,7 mg clomipramine)
ЕКСЦИПИЕНТИ:
За пълния списък на ексципиентите, виж
т. 6.1.
3.
ФАРМАЦЕВТИЧНА ФОРМА
Таблетки.
5 mg таблетка: кафяво-сива,
овално-продълговата, делима. Черти от
двете страни.
20 mg таблетка: кафяво-сива,
овално-продълговата, делима. С
маркировка ‘C/G’ от едната
страна, ‘G/N’ от другата и черти от
двете страни.
80 mg таблетка: кафяво-сива,
овално-продълговата, делима. С
маркировка ‘I/I’ от едната страна,
без маркировка от другата и черти от
двете страни.
4.
КЛИНИЧНИ ДАННИ
4.1
ВИДОВЕ ЖИВОТНИ, ЗА КОИТО Е
ПРЕДНАЗНАЧЕН ВМП
Кучета.
4.2
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ, ОПРЕДЕЛЕНИ ЗА
ОТДЕЛНИТЕ ВИДОВЕ ЖИВОТНИ
Като
помощно
средство
при
лечение
на
свързани
с
раздяла
разстройства
при
кучета,
проявяващи се с деструктивно
поведе
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 25-10-2021
Public Assessment Report Public Assessment Report Spanish 01-07-2016
Patient Information leaflet Patient Information leaflet Czech 25-10-2021
Public Assessment Report Public Assessment Report Czech 01-07-2016
Patient Information leaflet Patient Information leaflet Danish 25-10-2021
Public Assessment Report Public Assessment Report Danish 01-07-2016
Patient Information leaflet Patient Information leaflet German 25-10-2021
Public Assessment Report Public Assessment Report German 01-07-2016
Patient Information leaflet Patient Information leaflet Estonian 25-10-2021
Public Assessment Report Public Assessment Report Estonian 01-07-2016
Patient Information leaflet Patient Information leaflet Greek 25-10-2021
Public Assessment Report Public Assessment Report Greek 01-07-2016
Patient Information leaflet Patient Information leaflet English 25-10-2021
Public Assessment Report Public Assessment Report English 01-07-2016
Patient Information leaflet Patient Information leaflet French 25-10-2021
Public Assessment Report Public Assessment Report French 01-07-2016
Patient Information leaflet Patient Information leaflet Italian 25-10-2021
Public Assessment Report Public Assessment Report Italian 01-07-2016
Patient Information leaflet Patient Information leaflet Latvian 25-10-2021
Public Assessment Report Public Assessment Report Latvian 01-07-2016
Patient Information leaflet Patient Information leaflet Lithuanian 25-10-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 25-10-2021
Public Assessment Report Public Assessment Report Lithuanian 01-07-2016
Patient Information leaflet Patient Information leaflet Hungarian 25-10-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 25-10-2021
Public Assessment Report Public Assessment Report Hungarian 01-07-2016
Patient Information leaflet Patient Information leaflet Maltese 25-10-2021
Public Assessment Report Public Assessment Report Maltese 01-07-2016
Patient Information leaflet Patient Information leaflet Dutch 25-10-2021
Public Assessment Report Public Assessment Report Dutch 01-07-2016
Patient Information leaflet Patient Information leaflet Polish 25-10-2021
Public Assessment Report Public Assessment Report Polish 01-07-2016
Patient Information leaflet Patient Information leaflet Portuguese 25-10-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 25-10-2021
Public Assessment Report Public Assessment Report Portuguese 01-07-2016
Patient Information leaflet Patient Information leaflet Romanian 25-10-2021
Public Assessment Report Public Assessment Report Romanian 01-07-2016
Patient Information leaflet Patient Information leaflet Slovak 25-10-2021
Public Assessment Report Public Assessment Report Slovak 01-07-2016
Patient Information leaflet Patient Information leaflet Slovenian 25-10-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 25-10-2021
Public Assessment Report Public Assessment Report Slovenian 01-07-2016
Patient Information leaflet Patient Information leaflet Finnish 25-10-2021
Public Assessment Report Public Assessment Report Finnish 01-07-2016
Patient Information leaflet Patient Information leaflet Swedish 25-10-2021
Public Assessment Report Public Assessment Report Swedish 01-07-2016
Patient Information leaflet Patient Information leaflet Norwegian 25-10-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 25-10-2021
Patient Information leaflet Patient Information leaflet Icelandic 25-10-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 25-10-2021
Patient Information leaflet Patient Information leaflet Croatian 25-10-2021
Public Assessment Report Public Assessment Report Croatian 01-07-2016

Search alerts related to this product

View documents history